Literature DB >> 26608680

Controlling confounding of treatment effects in administrative data in the presence of time-varying baseline confounders.

David T Gilbertson1, Brian D Bradbury2, James B Wetmore1, Eric D Weinhandl1, Keri L Monda2, Jiannong Liu1, M Alan Brookhart3, Sally K Gustafson1, Tricia Roberts1, Allan J Collins1,4, Kenneth J Rothman5,6.   

Abstract

PURPOSE: Confounding, a concern in nonexperimental research using administrative claims, is nearly ubiquitous in claims-based pharmacoepidemiology studies. A fixed-length look-back window for assessing comorbidity from claims is common, but it may be advantageous to use all historical claims. We assessed how the strength of association between a baseline-identified condition and subsequent mortality varied by when the condition was measured and investigated methods to control for confounding.
METHODS: For Medicare beneficiaries undergoing maintenance hemodialysis on 1 January 2008 (n = 222 343), we searched all Medicare claims, 1 January 2001 to 31 December 2007, for four conditions representing chronic and acute diseases, and classified claims by number of months preceding the index date. We used proportional hazard models to estimate the association between time of condition and subsequent mortality. We simulated a confounded comorbidity-exposure relationship and investigated an alternative method of adjustment when the association between the condition and mortality varied by proximity to follow-up start.
RESULTS: The magnitude of the mortality hazard ratio estimates for each condition investigated decreased toward unity as time increased between index date and most recent manifestation of the condition. Simulation showed more biased estimates of exposure-outcome associations if proximity to follow-up start was not considered.
CONCLUSIONS: Using all-available claims information during a baseline period, we found that for all conditions investigated, the association between a comorbid condition and subsequent mortality varied considerably depending on when the condition was measured. Improved confounding control may be achieved by considering the timing of claims relative to follow-up start.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  administrative claims data; comorbid conditions; confounding; nonexperimental research; pharmacoepidemiology

Mesh:

Year:  2015        PMID: 26608680     DOI: 10.1002/pds.3922

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  12 in total

1.  Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform.

Authors:  Glenn M Chertow; Jiannong Liu; Keri L Monda; David T Gilbertson; M Alan Brookhart; Anne C Beaubrun; Wolfgang C Winkelmayer; Allan Pollock; Charles A Herzog; Akhtar Ashfaq; Til Sturmer; Kenneth J Rothman; Brian D Bradbury; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2016-02-25       Impact factor: 10.121

2.  A Comparative Study of Carvedilol Versus Metoprolol Initiation and 1-Year Mortality Among Individuals Receiving Maintenance Hemodialysis.

Authors:  Magdalene M Assimon; M Alan Brookhart; Jason P Fine; Gerardo Heiss; J Bradley Layton; Jennifer E Flythe
Journal:  Am J Kidney Dis       Date:  2018-04-10       Impact factor: 8.860

3.  Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.

Authors:  Magdalene M Assimon; M Alan Brookhart; Jennifer E Flythe
Journal:  J Am Soc Nephrol       Date:  2019-03-18       Impact factor: 10.121

4.  Antidepressant continuation in pregnancy and risk of gestational diabetes.

Authors:  Paige D Wartko; Noel S Weiss; Daniel A Enquobahrie; K C Gary Chan; Alyssa Stephenson-Famy; Beth A Mueller; Sascha Dublin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-07-12       Impact factor: 2.890

5.  Cohort restriction based on prior enrollment: Examining potential biases in estimating cancer and mortality risk.

Authors:  Susan M Shortreed; Eric Johnson; Carolyn M Rutter; Aruna Kamineni; Karen J Wernli; Jessica Chubak
Journal:  Obs Stud       Date:  2016-09-26

6.  Maternal Gestational Weight Gain in Relation to Antidepressant Continuation in Pregnancy.

Authors:  Paige D Wartko; Noel S Weiss; Daniel A Enquobahrie; Kwun Chuen Gary Chan; Alyssa Stephenson-Famy; Beth A Mueller; Sascha Dublin
Journal:  Am J Perinatol       Date:  2020-06-30       Impact factor: 1.862

7.  Association of Antidepressant Continuation in Pregnancy and Infant Birth Weight.

Authors:  Paige D Wartko; Noel S Weiss; Daniel A Enquobahrie; K C Gary Chan; Alyssa Stephenson-Famy; Beth A Mueller; Sascha Dublin
Journal:  J Clin Psychopharmacol       Date:  2021 Jul-Aug 01       Impact factor: 3.153

8.  The impact of the lookback period and definition of confirmatory events on the identification of incident cancer cases in administrative data.

Authors:  Jonas Czwikla; Kathrin Jobski; Tania Schink
Journal:  BMC Med Res Methodol       Date:  2017-08-14       Impact factor: 4.615

9.  Propensity Scores in Pharmacoepidemiology: Beyond the Horizon.

Authors:  John W Jackson; Ian Schmid; Elizabeth A Stuart
Journal:  Curr Epidemiol Rep       Date:  2017-11-06

10.  Updating and Validating the U.S. Veterans Affairs Frailty Index: Transitioning From ICD-9 to ICD-10.

Authors:  David Cheng; Clark DuMontier; Cenk Yildirim; Brian Charest; Chelsea E Hawley; Min Zhuo; Julie M Paik; Enzo Yaksic; J Michael Gaziano; Nhan Do; Mary Brophy; Kelly Cho; Dae H Kim; Jane A Driver; Nathanael R Fillmore; Ariela R Orkaby
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-06-14       Impact factor: 6.053

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.